Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

FDA Approves Merck’s KEYTRUDA® as Adjuvant Treatment for Patients with Stage IIB or IIC Melanoma

AmericanPharmaceuticalReviewDecember 07, 2021

Tag: Keytruda , melanoma , IIB

PharmaSources Customer Service